Asana Recovery’s Post

Small Molecules still remains a big part of the drug approval story in the midst of the all the cloud of ADCs, BiSpecifics etc.. At the end of the day, if something makes a patients lives easy, it is going to make a bigger impact. Another such example that I get very excited about is Macro-cyclisation techniques to target multiple targets at once with immense benefits of potential Low toxicity and high potency. https://lnkd.in/g9hRHQqT

The new system, which forms part of the ACG World’s Inspections Life Sciences Cloud Service and Compliance Gateway, enables the automatic verification of saleable returns through #product identifiers by routing requests and responses between #stakeholders. Shine Vijayan #healthcare #PharmaIndustrialIndia

CASE STUDY check out our latest case study showing how Dermavant Sciences was able to modernize their statistical computing environment seemingly overnight without delaying their drug development program. With a turnkey, validated, and centralized solution hosted in the cloud, they were able to keep their biometrics team up and running and with 24/7 support services.   Read the case study here: : https://lnkd.in/eeBQjDw2 #biostatistics #biometrics #cloudhosting #statisticalanalysis #clinicaldata

Pharmaceuticals need to combat pandemics quicker. https://buff.ly/44qawFL Imagine a world where seamless collaboration between Pharma companies, research firms, and regulatory bodies like the FDA is the norm, not the exception. This is the potential of cloud computing in the pharmaceutical industry. Beyond just enhancing collaboration, cloud computing also ensures the safety of your data even when the platform is shared. This innovative approach could be the game-changer in our fight against global health crises. Don't wait. Be part of this networked future for global health. Contact us today at +91 8657958773 or email us at marketing@epacts.in. Let's reshape health together! #DataSecurity #PharmaCollaboration #CloudComputing

https://lnkd.in/gNvZ__Xg How loose can loose be in drug approval? A slow creep towards irrelevance has started. Where are the guard rails and who sets them? Is it time to create another system where this and more is the norm? Yes there is always the other side, and need for surrogate quality of life endpoints. Are they murky spots or better said murky endpoints in the data pond? Too many questions, that’s the point.

Update!! on the Drug of the year, read and heed!

https://lnkd.in/gTdMNMiR Will be interesting to see if the usage drops as much as they are forecasting

When everything is critical, nothing is critical. Not every parameter is critical to quality. SimpliDATA helps you to not forget a parameter that might just be critical. https://zurl.co/iD5m

When everything is critical, nothing is critical. Not every parameter is critical to quality. SimpliDATA helps you to not forget a parameter that might just be critical. https://zurl.co/iD5m